查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1606413

子宮內膜癌市場，按癌症類型、治療類型、診斷方法、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Endometrial Cancer Market, By Type of Cancer, By Type of Therapy, By Diagnosis Method, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年子宮內膜癌市場規模為263.9453億美元，2024年至2032年複合年成長率為5.80%。

子宮內膜癌市場-市場動態

子宮內膜癌盛行率的增加預計將推動市場擴張。

隨著子宮內膜癌病例數量的增加，對高效率診斷工具和服務的需求不斷增加。這包括使用超音波和 MRI 等成像技術以及活體組織切片程序。提高意識和篩檢實踐可以促進早期診斷，這對於提高治療效果至關重要。根據世界癌症研究基金會國際報告，2022 年報告了 420,368 例子宮內膜癌新病例。然而，獲得醫療服務的機會有限可能會阻礙市場成長。

子宮內膜癌市場 - 主要見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032）每年將以 5.80% 左右的複合年成長率成長

根據癌症類型細分，預計子宮內膜癌將在 2023 年呈現最大市場佔有率

根據治療類型細分，化療是 2023 年的主導類型

根據診斷方法細分，活體組織切片是2023年的主導類型

按地區分類，北美是 2023 年的主要收入來源

子宮內膜癌市場-細分分析：

全球子宮內膜癌市場根據癌症類型、治療類型、診斷方法和地區進行細分。

根據癌症類型，市場分為兩類：子宮內膜癌、子宮肉瘤和其他。子宮內膜癌在市場上佔據主導地位。子宮內膜癌是一種起源於子宮內膜（子宮內膜）的癌症。它佔子宮癌的大部分，通常在停經後婦女中被診斷出來。

根據治療類型，市場分為三個部分：免疫療法、放射療法、化療和其他。化療領域在市場上佔據主導地位。它被廣泛認為是晚期、復發性或侵襲性子宮內膜癌的主要治療選擇之一。

根據診斷方法，市場分為四大類：切片檢查、骨盆超音波、子宮腔鏡檢查、CT 掃描等。活體組織切片在市場上佔據主導地位。活體組織切片在子宮內膜癌的早期檢測和診斷中的重要性至關重要，因為它們直接影響治療選擇以及對診斷工具和方法的需求。

子宮內膜癌市場 - 地理洞察

北美領先市場，主要歸功於診斷方法的進步。該地區的特點是擁有強大的醫療保健系統，包括眾多成熟的癌症治療中心和專業設施，全部配備了尖端的診斷技術。該基礎設施促進了癌症護理的整體方法，包括診斷和治療。每年，約有 40 萬名患者在 NCI 指定癌症中心被診斷出罹患癌症。由於意識的提高和篩檢計劃的實施，歐洲成為市場成長的第二大地區。隨著各個地區的意識、診斷能力和治療替代方案的不斷增強，全球市場預計將進一步成長。

子宮內膜癌市場-競爭格局：

在診斷、治療方式和致力於提高患者治療效果的新興技術創新的推動下，子宮內膜癌市場呈現高度競爭。許多公司正在爭奪活體組織切片儀器、化療藥物、標靶治療和免疫治療等領域的市場佔有率。人們正在對研發進行大量投資，以創造新的治療方案，包括免疫療法、標靶療法和聯合療法。液體活體組織切片和基因檢測等進步因其在早期檢測和個人化治療策略方面的潛力而日益得到認可。能夠有效通過法規核准流程的公司將能夠獲得競爭優勢，特別是在免疫療法等快速發展的領域。

最新進展：

2024 年 2 月 5 日，諾華宣布已達成協議，針對 MorphoSys AG 發起自願公開收購競標。

最近一項創新抗體藥物的試驗，直接對癌細胞進行強效化療，目前正在針對晚期或復發性子宮內膜癌的患者進行 III 期研究。

目錄

第1章：子宮內膜癌市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 以癌症類型分類的子宮內膜癌市場片段
    • 依治療類型分類的子宮內膜癌市場片段
    • 以診斷方法分類的子宮內膜癌市場片段
    • 按國家/地區分類的子宮內膜癌市場片段
    • 按地區分類的子宮內膜癌市場片段
  • 競爭洞察

第 3 章：子宮內膜癌主要市場趨勢

  • 子宮內膜癌市場促進因素
    • 市場促進因素的影響分析
  • 子宮內膜癌市場限制
    • 市場限制影響分析
  • 子宮內膜癌市場機會
  • 子宮內膜癌市場未來趨勢

第 4 章：子宮內膜癌產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：子宮內膜癌市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：子宮內膜癌市場模式

  • 2023 年子宮內膜癌市佔分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：子宮內膜癌市場 - 依癌症類型

  • 概述
    • 按癌症類型分類的細分市場佔有率分析
    • 子宮內膜癌
    • 子宮肉瘤
    • 其他

第 8 章：子宮內膜癌市場 - 依治療類型

  • 概述
    • 按治療類型分類的細分市場佔有率分析
    • 免疫治療
    • 放射治療
    • 化療
    • 其他

第 9 章：子宮內膜癌市場 - 依診斷方法

  • 概述
    • 依診斷方法進行細分市場佔有率分析
    • 活體組織切片
    • 骨盆腔超音波檢查
    • 子宮腔鏡檢查
    • CT掃描
    • 其他

第 10 章：子宮內膜癌市場 - 依地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美子宮內膜癌主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按癌症類型）
    • 北美市場規模和預測（按治療類型）
    • 北美市場規模和預測（按診斷方法）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲子宮內膜癌主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按癌症類型）
    • 歐洲市場規模和預測（按治療類型）
    • 歐洲市場規模和預測（按診斷方法）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區子宮內膜癌主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按癌症類型）
    • 按治療類型分類的亞太市場規模和預測
    • 按診斷方法分類的亞太市場規模和預測
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲子宮內膜癌主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按癌症類型）
    • 拉丁美洲市場規模與預測（按治療類型）
    • 拉丁美洲市場規模和預測（按診斷方法）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲子宮內膜癌主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按癌症類型）
    • 中東和非洲市場規模和預測（按治療類型）
    • 中東和非洲市場規模及預測（按診斷方法）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 子宮內膜癌產業

  • 競爭儀表板
  • 公司簡介
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Merck & Co. Inc.
    • Novartis International AG
    • AstraZeneca PLC
    • Genentech Inc. (Roche)
    • GlaxoSmithKline PLC
    • Johnson & Johnson
    • Eli Lilly and Company
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Sanofi SA
    • Hoffmann-La Roche Ltd.
    • Exelixis Inc.
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4183

REPORT HIGHLIGHT

Endometrial Cancer Market size was valued at USD 26,394.53 million in 2023, expanding at a CAGR of 5.80% from 2024 to 2032.

Endometrial cancer is a form of cancer that originates from the cellular growth within the uterus, which is the hollow, pear-shaped organ in the pelvis responsible for fetal development. In the United States, it is the most prevalent cancer impacting the reproductive system of women and individuals assigned female at birth (AFAB). This type of cancer predominantly occurs following menopause. Approximately 3% of women and individuals with AFAB will be diagnosed with uterine cancer at some stage in their lives, with around 65,000 new cases reported annually.

Endometrial Cancer Market- Market Dynamics

The increasing prevalence of endometrial cancer is anticipated to propel market expansion.

As the number of endometrial cancer cases escalates, there is an increasing demand for efficient diagnostic tools and services. This encompasses the utilization of imaging technologies, such as ultrasound and MRI, along with biopsy procedures. Improved awareness and screening practices can facilitate earlier diagnoses, which are crucial for enhancing treatment outcomes. According to the World Cancer Research Fund International, there were 420,368 new cases of endometrial cancer reported in 2022. The ongoing research and development, along with advancements in treatment modalities, may present growth opportunities for the market. However, limited access to healthcare services could hinder market growth.

Endometrial Cancer Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2024-2032)

Based on Type of Cancer segmentation, Endometrial Carcinoma was predicted to show maximum market share in the year 2023

Based on Type of Therapy segmentation, Chemotherapy was the leading type in 2023

Based on Diagnosis Method segmentation, Biopsy was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Endometrial Cancer Market- Segmentation Analysis:

The Global Endometrial Cancer Market is segmented on the basis of Type of Cancer, Type of Therapy, Diagnosis Method, and Region.

The market is divided into two categories based on the Type of Cancer: Endometrial Carcinoma, Uterine Sarcomas, and Others. Endometrial Carcinoma dominates the market. Endometrial carcinoma is a type of cancer that originates in the lining of the uterus (endometrium). It accounts for the majority of uterine cancers and is usually diagnosed in postmenopausal women.

The market is classified into three segments according to the Type of Therapy: Immunotherapy, Radiation Therapy, Chemotherapy, and Others. The Chemotherapy segment holds a dominant position within the market. It is widely recognized as one of the primary treatment options for advanced, recurrent, or aggressive types of endometrial cancer.

The market is segmented into four categories according to the Diagnosis Method: Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, and others. Biopsy holds a predominant position in the market. The significance of biopsies in the early detection and diagnosis of endometrial cancer is paramount, as they directly affect treatment choices and the demand for diagnostic tools and methodologies.

Endometrial Cancer Market- Geographical Insights

North America leads the market, primarily due to advancements in diagnostic methodologies. The region is characterized by a strong healthcare system that includes numerous established cancer treatment centers and specialized facilities, all equipped with cutting-edge diagnostic technologies. This infrastructure facilitates a holistic approach to cancer care, encompassing both diagnosis and treatment. Annually, around 400,000 patients are diagnosed with cancer at NCI-Designated Cancer Centers. Europe ranks as the second largest region for market growth, attributed to heightened awareness and the implementation of screening programs. The global market is anticipated to grow further as awareness, diagnostic capabilities, and treatment alternatives continue to enhance across various regions.

Endometrial Cancer Market- Competitive Landscape:

The Endometrial Cancer Market exhibits a high level of competition, propelled by innovations in diagnostics, treatment modalities, and emerging technologies focused on enhancing patient outcomes. Numerous firms are competing for market share in sectors such as biopsy instruments, chemotherapeutic drugs, targeted therapies, and immunotherapies. Significant investments in research and development are being made to create novel treatment options, including immunotherapies, targeted therapies, and combination approaches. Advancements such as liquid biopsy and genetic testing are increasingly recognized for their potential in early detection and personalized treatment strategies. Companies that can efficiently navigate the regulatory approval process are positioned to gain a competitive edge, particularly in rapidly evolving areas like immunotherapy.

Recent Developments:

On February 5, 2024, Novartis announced that it has reached an agreement to initiate a voluntary public takeover bid for MorphoSys AG, a biopharmaceutical company based in Germany that specializes in the development of innovative oncology treatments.

A recent trial of an innovative antibody drug, which administers powerful chemotherapy directly to cancer cells, is progressing to a phase III study for patients suffering from advanced or recurrent endometrial cancer.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ENDOMETRIAL CANCER MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • Bristol Myers Squibb Company
  • Merck & Co. Inc.
  • Novartis International AG
  • AstraZeneca PLC
  • Genentech Inc. (Roche)
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Eli Lilly and Company
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Sanofi S.A.
  • Hoffmann-La Roche Ltd.
  • Exelixis Inc.
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY TYPE OF CANCER- MARKET ANALYSIS, 2019 - 2032

  • Endometrial Carcinoma
  • Uterine Sarcomas
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY TYPE OF THERAPY- MARKET ANALYSIS, 2019 - 2032

  • Immunotherapy
  • Radiation Therapy
  • Chemotherapy
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY DIAGNOSIS METHOD- MARKET ANALYSIS, 2019 - 2032

  • Biopsy
  • Pelvic Ultrasound
  • Hysteroscopy
  • CT scan
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Endometrial Cancer Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Endometrial Cancer Market Snippet by Type of Cancer
    • 2.1.2. Endometrial Cancer Market Snippet by Type of Therapy
    • 2.1.3. Endometrial Cancer Market Snippet by Diagnosis Method
    • 2.1.4. Endometrial Cancer Market Snippet by Country
    • 2.1.5. Endometrial Cancer Market Snippet by Region
  • 2.2. Competitive Insights

3. Endometrial Cancer Key Market Trends

  • 3.1. Endometrial Cancer Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Endometrial Cancer Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Endometrial Cancer Market Opportunities
  • 3.4. Endometrial Cancer Market Future Trends

4. Endometrial Cancer Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Endometrial Cancer Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Endometrial Cancer Market Landscape

  • 6.1. Endometrial Cancer Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Endometrial Cancer Market - By Type of Cancer

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type of Cancer, 2023 & 2032 (%)
    • 7.1.2. Endometrial Carcinoma
    • 7.1.3. Uterine Sarcomas
    • 7.1.4. Others

8. Endometrial Cancer Market - By Type of Therapy

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type of Therapy, 2023 & 2032 (%)
    • 8.1.2. Immunotherapy
    • 8.1.3. Radiation Therapy
    • 8.1.4. Chemotherapy
    • 8.1.5. Others

9. Endometrial Cancer Market - By Diagnosis Method

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Diagnosis Method, 2023 & 2032 (%)
    • 9.1.2. Biopsy
    • 9.1.3. Pelvic Ultrasound
    • 9.1.4. Hysteroscopy
    • 9.1.5. CT scan
    • 9.1.6. Others

10. Endometrial Cancer Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Endometrial Cancer Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Endometrial Cancer Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Endometrial Cancer Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Endometrial Cancer Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Endometrial Cancer Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Endometrial Cancer Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
    • 11.2.2. Bristol Myers Squibb Company
    • 11.2.3. Merck & Co. Inc.
    • 11.2.4. Novartis International AG
    • 11.2.5. AstraZeneca PLC
    • 11.2.6. Genentech Inc. (Roche)
    • 11.2.7. GlaxoSmithKline PLC
    • 11.2.8. Johnson & Johnson
    • 11.2.9. Eli Lilly and Company
    • 11.2.10. AbbVie Inc.
    • 11.2.11. Teva Pharmaceutical Industries Ltd.
    • 11.2.12. Bayer AG
    • 11.2.13. Sanofi S.A.
    • 11.2.14. Hoffmann-La Roche Ltd.
    • 11.2.15. Exelixis Inc.
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us